S. Stilgenbauer

Publications615
h-index82
Citations27,756
Highly Influential Citations1,118
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • W. Wierda
  • 1,087 Publications, 34,974 Citations
  • J. Byrd
  • 1,326 Publications, 52,711 Citations
  • T. Kipps
  • 859 Publications, 53,057 Citations
  • M. Keating
  • 1,160 Publications, 64,396 Citations
  • Publications
  • Influence
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
BACKGROUND Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemotherapy. Effective therapies… Expand
  • 1,235
  • 65
  • Open Access
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
BACKGROUND The monoclonal anti-CD20 antibody rituximab, combined with chemotherapeutic agents, has been shown to prolong overall survival in physically fit patients with previously untreated chronic… Expand
  • 1,016
  • 63
  • Open Access
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
BACKGROUND Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor,… Expand
  • 1,042
  • 58
  • Open Access
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
BACKGROUND Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors and resistance… Expand
  • 680
  • 38
  • Open Access
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias.
Conventional cytogenetic analysis in B-cell chronic lymphocytic leukemia (B-CLL) has been very difficult, and the prognostic significance of specific chromosome aberrations is under discussion.… Expand
  • 769
  • 27
  • Open Access
MYC stimulates EZH2 expression by repression of its negative regulator miR-26a.
The MYC oncogene, which is commonly mutated/amplified in tumors, represents an important regulator of cell growth because of its ability to induce both proliferation and apoptosis. Recent evidence… Expand
  • 363
  • 27
Matrix‐based comparative genomic hybridization: Biochips to screen for genomic imbalances
Comparative genomic hybridization (CGH) to metaphase chromosomes has been widely used for the genome‐wide screening of genomic imbalances in tumor cells. Substitution of the chromosome targets by a… Expand
  • 1,042
  • 26
From pathogenesis to treatment of chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia (CLL) has several unique features that distinguish it from other cancers. Most CLL tumour cells are inert and arrested in G0/G1 of the cell cycle and there is only a… Expand
  • 541
  • 26
  • Open Access
TP53 mutation and survival in chronic lymphocytic leukemia.
PURPOSE The precise prognostic impact of TP53 mutation and its incorporation into treatment algorithms in chronic lymphocytic leukemia (CLL) is unclear. We set out to define the impact of TP53… Expand
  • 452
  • 25
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
BACKGROUND Deletion of chromosome 17p (del[17p]) in patients with chronic lymphocytic leukaemia confers very poor prognosis when treated with standard chemo-immunotherapy. Venetoclax is an oral… Expand
  • 428
  • 25
  • Open Access